Core Insights - Bristol Myers Squibb launched the COBENFY Connections initiative to address the stigma surrounding schizophrenia and promote open conversations about the condition [1][4] - The initiative features personal stories from individuals living with schizophrenia, including culinary expert Gail Simmons, who shares her family's experience [1][3] - COBENFY is an oral medication indicated for the treatment of schizophrenia in adults, combining xanomeline and trospium chloride [8][9] Company Overview - Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases [28] - The company aims to create supportive environments for individuals affected by schizophrenia through initiatives like COBENFY Connections [4] Industry Context - Schizophrenia affects nearly 24 million people globally, with 2.8 million in the United States, making it one of the leading causes of disability worldwide [6] - The initiative seeks to empower individuals with schizophrenia and their families by fostering community connections and sharing experiences [2][4]